MedTrace Logo

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

NCT06896994 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-04-27

No results posted yet for this study

Summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

esketamine group

In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

DRUG

control group

receiving the combination of pregabalin and duloxetine

Sponsors & Collaborators

  • Beijing Xiaotangshan Hospital

    collaborator OTHER

  • The First Hospital of Fangshan District,Beijing

    collaborator OTHER

  • Beijing Ditan Hospital

    collaborator OTHER

  • Hengshui People's Hospital

    collaborator OTHER

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Fang Luo, M.D. · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-04-01
Completion
2026-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06896994 on ClinicalTrials.gov